Error in the Exclusion of Participants From Analysis in the ACTIV-6 Platform Randomized Clinical Trial

To the Editor On behalf of my coauthors, I write to explain errors that we identified in the Original Investigation “Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial,” published online on February 20, 2023, and in the March 21, 2023, print issue of JAMA. This article reported the findings of the double-blind Accelerating COVID-19 Therapeutic Interventions and Vaccines 6 (ACTIV-6) platform randomized clinical trial of 1206 US adults with COVID-19 who received a targeted dose of 600 μg/kg of ivermectin or placebo for 6 days during February 2022 to July 2022. The primary outcome was time to sustained recovery, defined as at least 3 consecutive days without symptoms. As we reported, “the median time to sustained recovery was 11 days in the ivermectin group and 11 days in the placebo group. In this largely vaccinated (84%) population, the posterior probability that ivermectin reduced symptom duration by more than 1 day was less than 0.1%.”